J Korean Cancer Assoc.  1998 Apr;30(2):225-230.

Combination Chemotherapy with Cisplatin , Etoposide , and Ifosfamide ( PIE ) in the Advanced Non - Small Cell Lung Cancer

• Shin SW
• Kim BS
• Shin JJ
• Kim YH
• Kang KH
• Choi YH
• Kim KT
• Kim JS

Abstract

PURPOSE
Combination chemotherapy with cisplatin and etoposide have been considered as one of the chemotherpy regimen for non small cell lung cacer(NSCLC) with the response rate of 20~40%. Ifosfamide is one of the most active agent against NSCLC. And so, we initiated a phase II trial for advanced NSCLC to determine the effect of PIE(cisplatin, ifosfamide, etoposide) regimen.
MATERIALS AND METHODS
36 patients with inoperable non-small cell lung cancer who had no prior systemic chemotherapy were treated with combined ifosfamide (1,800 mg/m2 plus mesna 1,100 mg/m2 by intravenous continuous infusion daily for 3 days) with cisplatin (20 mg/m2 intravenous for 3 days) and etoposide (80 mg/m2 intravenous for 3 days). We evaluated the response rate, survival and toxicities of these patients.
RESULTS
The objective response rate was 28%(CR; 2/36, 6%, PR; 8/36, 22%). Among 10 responders, 7 patients were in good ECOG performance status(0~1). The mean survival of all these patients were 43 weeks(8~141 weeks); the responding patients survived longer than the non-responders(median survival; 59 weeks vs 28 weeks, p<0.05). The toxicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION
We concluded that PIE regimen is effective in the treatment of advanced non-small cell lung cancer with acceptable toxicities and long-term follow up is warranted.

Keyword

Ifosfamide; Cisplatin; Etoposide; Non-small cell lung cancer; Chemotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung
Cisplatin*
Drug Therapy
Drug Therapy, Combination*
Etoposide*
Follow-Up Studies
Humans
Ifosfamide*
Lung
Mesna
Small Cell Lung Carcinoma*
Survival Rate
Cisplatin
Etoposide
Ifosfamide
Mesna